SEK 36.5
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of HNSA.ST is 85 and suggests 133% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
